RESUMEN
The COVID-19 pandemic caused by SARS-CoV2 has raised several important health concerns, not least increased mortality and morbidity. SARS-CoV2 can infect the central nervous system via hematogenous or transneuronal routes, acting through different receptors including ACE2, DPP4, and neuropilin 1 and cause several issues, including the focus here, cerebellitis. The cerebellum is an essential part of the CNS located adjacent to the brainstem with a complex micro and macroscopic structure. The cerebellum plays several physiological roles, such as coordination, cognition, and executive functioning. Damage to the cerebellum can lead to incoordination and ataxia. In our narrative review, we searched different databases from 2021 to 2022 with the keywords cerebellum and COVID-19; 247 studies were identified and reviewed, focusing on clinical studies and excluding non-clinical studies; 56 studies were finally included for analysis. SARS-CoV2 infection of the cerebellum can be seen to be assessed through many methods such as MRI, PET, CT, postmortem studies, and histological findings. These methodological studies have demonstrated that cerebellar infection with COVID-19 can bring about several sequelae: thrombosis, microbleed, hemorrhage, stroke, autoantibody production, ataxia, and widespread inflammation in the cerebellum. Such central effects are likely to exacerbate the known multiorgan effects of SARS-CoV2 and should also be considered as part of disease prognosis.
Asunto(s)
COVID-19 , Humanos , COVID-19/complicaciones , Pandemias , SARS-CoV-2 , ARN Viral , Ataxia/etiologíaRESUMEN
We present a woman in her 40s who arrived at the emergency room with hypertension and optic ataxia. Her medical history is only relevant for obesity. Her lumbar puncture revealed high intracranial pressure and lymphocytic pleocytosis, and her neuroimaging tests, including angiography and venography, were normal. The patient improved after a cerebrospinal fluid drainage with a lumbar puncture, and her clinical manifestations resolved in parallel to the lymphocytic pleocytosis.The patient was diagnosed with a syndrome of transient headache and neurological deficits with cerebrospinal fluid lymphocytosis and fully recovered 21 days after her discharge.
Asunto(s)
Linfocitosis , Enfermedades del Sistema Nervioso , Ataxia/etiología , Femenino , Humanos , Leucocitosis , Linfocitosis/diagnóstico , SíndromeRESUMEN
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Asunto(s)
COVID-19 , Síndrome de Guillain-Barré , Ataxia/etiología , Vacuna BNT162 , COVID-19/complicaciones , Vacunas contra la COVID-19/efectos adversos , Disgeusia/etiología , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/tratamiento farmacológico , Síndrome de Guillain-Barré/etiología , Humanos , ARN Mensajero , SARS-CoV-2 , VacunaciónAsunto(s)
COVID-19 , Ataxia Cerebelosa , Mioclonía , Humanos , COVID-19/complicaciones , SARS-CoV-2 , Ataxia/etiología , SíndromeAsunto(s)
Infecciones por Coronavirus/fisiopatología , Síndrome de Guillain-Barré/fisiopatología , Neumonía Viral/fisiopatología , Adulto , Anciano , Ageusia/etiología , Astenia/etiología , Ataxia/etiología , COVID-19 , Infecciones por Coronavirus/complicaciones , Diarrea/etiología , Parálisis Facial/etiología , Femenino , Síndrome de Guillain-Barré/líquido cefalorraquídeo , Síndrome de Guillain-Barré/complicaciones , Síndrome de Guillain-Barré/terapia , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , Mialgia/etiología , Conducción Nerviosa , Trastornos del Olfato/etiología , Pandemias , Paraparesia/etiología , Parestesia/etiología , Neumonía Viral/complicaciones , Cuadriplejía/etiología , Reflejo Anormal , Insuficiencia Respiratoria/etiologíaRESUMEN
Opsoclonus-myoclonus-ataxia syndrome is a heterogeneous constellation of symptoms ranging from full combination of these three neurological findings to varying degrees of isolated individual sign. Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered. As a neuro-inflammatory disorder, one would expect to observe opsoclonus-myoclonus syndrome after a prevalent viral infection in a pandemic scale, as it has been the case for many other neuro-inflammatory syndromes. We report seven cases of opsoclonus-myoclonus syndrome presumably parainfectious in nature and discuss their phenomenology, their possible pathophysiological relationship to COVID-19, and diagnostic and treatment strategy in each case. Finally, we review the relevant data in the literature regarding the opsoclonus-myoclonus syndrome and possible similar cases associated with COVID-19 and its diagnostic importance for clinicians in various fields of medicine encountering COVID-19 patients and its complications.